Risk of impairment the morning after use of sleep aid drugs
Silver Spring, Maryland–(ENEWSPF)–May 15, 2014. The U.S. Food and Drug Administration today announced it required the manufacturer of the sleep drug Lunesta (eszopiclone) to change the drug label and lower the current recommended starting dose. Data show that eszopiclone levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving, even if they feel fully…
